Products for Research Use Only

DOTA-PSMA-EB-01

CAT: 0804-HY-158266-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-158266-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM) .DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors[1]. DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
Product Name Alternative
LNC1003
UNSPSC
12352209
Target
PSMA; Radionuclide-Drug Conjugates (RDCs)
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dota-psma-eb-01.html
Purity
97.02
Solubility
DMSO : 6.67 mg/mL (ultrasonic)
Smiles
CC1=C(C=CC(C2=CC(C)=C(C=C2)NC([C@@H](NC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)CCCCNC(CCOCCOCCC(NC[C@H]4CC[C@@H](CC4)C(N[C@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CC5=CC=C6C=CC=CC6=C5)=O)=O)=O)=O)=C1)/N=N/C7=C(C8=C(C(S(=O)(O)=O)=CC(S(=O)(O)=O)=C8N)C=C7)O
Molecular Formula
C87H115N15O28S2
Molecular Weight
1883.06
References & Citations
[1]Wen X, et al. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023 Jul;50 (9) :2846-2860.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
RDC Peptide